• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国北方女性乳腺癌患者队列中Her-2、p53、Ki-67表达及临床病理特征的比较研究

Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients.

作者信息

Ding Li, Zhang Zijin, Xu Yan, Zhang Yongqiang

机构信息

a Department of Oncology , Beijing Hospital, National Center of Gerontology , Beijing , China.

出版信息

Bioengineered. 2017 Jul 4;8(4):383-392. doi: 10.1080/21655979.2016.1235101. Epub 2017 Jan 11.

DOI:10.1080/21655979.2016.1235101
PMID:28075663
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5553327/
Abstract

The objective was to study the relationship among Her-2, Ki-67, p53 expression and the clinicopathologic characteristics of breast cancer in the patients of northern China. Expression of Her-2, Ki-67, p53 and clinical characteristics of 260 breast cancer patients were retrospectively studied. Her-2 overexpression led to higher incidence rates of infiltrating ductal carcinoma and axillary lymph node metastasis, bigger diameters of the primary tumors, later pTNM staging, and a lower incidence rate of ductal carcinoma in situ (p < 0.05). High expression of ER and PR led to fewer patients classified histologically in higher grade (p = 0.001), while high expression of Ki-67 and p53 caused more patients classified histologically in higher grade (p = 0.001). In patients histologically classified in grade 1 and 2, the expression of Ki-67 and p53 was significantly (p = 0.001) higher, and the expression of ER and PR was significantly lower, in Her-2 positive patients than Her-2 negative patients. Breast cancer with Her-2 overexpression was more likely to recur and metastasize than Her-2 negative breast cancer. Higher coincidence of high expression of p53 and Ki-67 with Her-2 overexpression and more progressed tumors suggested that in addition to p53, Ki-67 might also be a prognostic biomarker of breast cancer.

摘要

目的是研究中国北方乳腺癌患者中Her-2、Ki-67、p53表达与临床病理特征之间的关系。回顾性研究了260例乳腺癌患者的Her-2、Ki-67、p53表达及临床特征。Her-2过表达导致浸润性导管癌和腋窝淋巴结转移的发生率更高,原发肿瘤直径更大,pTNM分期更晚,原位导管癌发生率更低(p<0.05)。ER和PR高表达导致组织学分级较高的患者较少(p=0.001),而Ki-67和p53高表达导致组织学分级较高的患者较多(p=0.001)。在组织学分级为1级和2级的患者中,Her-2阳性患者的Ki-67和p53表达显著更高(p=0.001),ER和PR表达显著更低。Her-2过表达的乳腺癌比Her-2阴性乳腺癌更易复发和转移。p53和Ki-67高表达与Her-2过表达的高一致性以及更多进展期肿瘤表明,除p53外,Ki-67也可能是乳腺癌的预后生物标志物。

相似文献

1
Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients.中国北方女性乳腺癌患者队列中Her-2、p53、Ki-67表达及临床病理特征的比较研究
Bioengineered. 2017 Jul 4;8(4):383-392. doi: 10.1080/21655979.2016.1235101. Epub 2017 Jan 11.
2
Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alpha, high Ki-67 and bcl-2, and low p53.同时性双侧乳腺癌:一种HER-2和雌激素受体α常共同表达、Ki-67和bcl-2水平高且p53水平低的类型。
Int J Surg Pathol. 2005 Jul;13(3):239-46. doi: 10.1177/106689690501300302.
3
Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.HER-2/neu蛋白过表达与浸润性导管癌其他预后及预测因素的相关性
In Vivo. 2007 Jul-Aug;21(4):673-8.
4
Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.在乳腺癌筛查项目中选择的无淋巴结转移乳腺癌人群中,肿瘤大小与 Ki-67、p53 和 BCL2 的免疫组化表达之间的关系。
Anticancer Res. 2014 Jan;34(1):269-73.
5
Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.乳腺癌中雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER-2/neu,即C-erb B 2)反应模式与组织学分级、肿瘤大小及淋巴结状态的比较
Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):553-6.
6
Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.浸润性淋巴细胞、肿瘤特征与早期乳腺癌患者复发。
Am J Clin Oncol. 2013 Jun;36(3):224-31. doi: 10.1097/COC.0b013e3182467d90.
7
Clinicopathologic features of breast cancer patients with type 2 diabetes mellitus in southwest of China.中国西南地区 2 型糖尿病乳腺癌患者的临床病理特征。
Med Oncol. 2014 Jan;31(1):788. doi: 10.1007/s12032-013-0788-0. Epub 2013 Dec 12.
8
HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.HER-2/neu和p53过表达作为30岁及以下女性乳腺癌的生物标志物。
Cancer. 2005 Mar 1;103(5):900-5. doi: 10.1002/cncr.20850.
9
p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.p53在腋窝淋巴结阴性乳腺癌中的研究:一项关于流行病学危险因素、组织学特征及预后的免疫组化研究
J Clin Oncol. 1995 Apr;13(4):821-30. doi: 10.1200/JCO.1995.13.4.821.
10
Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma.乳腺浸润性导管癌中E-钙黏蛋白表达与常规免疫组化指标的相关性
Cancer Biomark. 2009;5(1):1-8. doi: 10.3233/CBM-2009-0551.

引用本文的文献

1
Molecular signatures of breast cancer in the Iranian population: a review of cell growth and cell cycle regulators.伊朗人群乳腺癌的分子特征:细胞生长与细胞周期调控因子综述
J Cancer Res Clin Oncol. 2025 Sep 11;151(9):255. doi: 10.1007/s00432-025-06301-y.
2
Expression Patterns of ER, PR, HER-2/neu and p53 in Association with Nottingham Tumour Grade in Breast Cancer Patients.乳腺癌患者中 ER、PR、HER-2/neu 和 p53 的表达模式与 Nottingham 肿瘤分级的关系。
Sultan Qaboos Univ Med J. 2023 Nov;23(4):526-533. doi: 10.18295/squmj.7.2023.044. Epub 2023 Nov 30.
3
A nomogram based on combining clinical features and contrast enhanced ultrasound is not able to identify Her-2 over-expressing cancer from other breast cancers.基于临床特征与超声造影相结合的列线图无法从其他乳腺癌中识别出Her-2过表达癌。
Front Oncol. 2023 Jan 26;13:1035645. doi: 10.3389/fonc.2023.1035645. eCollection 2023.
4
A comparison of Chinese multicenter breast cancer database and SEER database.中国多中心乳腺癌数据库与 SEER 数据库的比较。
Sci Rep. 2022 Jun 21;12(1):10395. doi: 10.1038/s41598-022-14573-4.
5
CCDC106 promotes the proliferation and invasion of ovarian cancer cells by suppressing p21 transcription through a p53-independent pathway.CCDC106 通过非依赖 p53 通路抑制 p21 转录从而促进卵巢癌细胞的增殖和侵袭。
Bioengineered. 2022 Apr;13(4):10956-10972. doi: 10.1080/21655979.2022.2066759.
6
Tumor-associated neutrophils activated by tumor-derived CCL20 (C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1 (PD-L1) in breast cancer.肿瘤来源的 CCL20(C 型趋化因子配体 20)激活的肿瘤相关中性粒细胞通过程序性死亡配体 1(PD-L1)促进乳腺癌中的 T 细胞免疫抑制。
Bioengineered. 2021 Dec;12(1):6996-7006. doi: 10.1080/21655979.2021.1977102.
7
Pitfalls and Caveats in Applying Chromogenic Immunostaining to Histopathological Diagnosis.应用显色免疫组化染色进行组织病理学诊断的陷阱和注意事项。
Cells. 2021 Jun 15;10(6):1501. doi: 10.3390/cells10061501.
8
Associations of Estrogen Receptor, Progesterone Receptor, Human Epidemic Growth Factor Receptor-2 and Ki-67 with Ultrasound Signs and Prognosis of Breast Cancer Patients.雌激素受体、孕激素受体、人表皮生长因子受体-2及Ki-67与乳腺癌患者超声征象及预后的相关性
Cancer Manag Res. 2021 Jun 9;13:4579-4586. doi: 10.2147/CMAR.S276422. eCollection 2021.
9
ZIC1 acts a tumor suppressor in breast cancer by targeting survivin.ZIC1 通过靶向生存素在乳腺癌中发挥肿瘤抑制作用。
Int J Oncol. 2018 Sep;53(3):937-948. doi: 10.3892/ijo.2018.4450. Epub 2018 Jun 21.

本文引用的文献

1
The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients.乳腺癌中Ki-67与其他预后因素的相关性:一项针对伊朗患者的研究。
Indian J Med Paediatr Oncol. 2016 Apr-Jun;37(2):95-9. doi: 10.4103/0971-5851.180136.
2
Expression of p53 Breast Cancer in Kurdish Women in the West of Iran: a Reverse Correlation with Lymph Node Metastasis.伊朗西部库尔德女性中p53在乳腺癌中的表达:与淋巴结转移呈负相关。
Asian Pac J Cancer Prev. 2016;17(3):1261-4.
3
Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.乳腺癌中Ki67的表达。沙特患者中与预后标志物及临床病理参数的相关性
Saudi Med J. 2016 Feb;37(2):137-41. doi: 10.15537/smj.2016.2.12285.
4
Molecular Profiling of Breast Carcinoma in Almadinah, KSA: Immunophenotyping and Clinicopathological Correlation.沙特阿拉伯麦地那乳腺癌的分子剖析:免疫表型分析及临床病理相关性研究
Asian Pac J Cancer Prev. 2015;16(17):7819-24. doi: 10.7314/apjcp.2015.16.17.7819.
5
Current and emerging breast cancer biomarkers.当前及新出现的乳腺癌生物标志物
J Cancer Res Ther. 2015 Jul-Sep;11(3):508-13. doi: 10.4103/0973-1482.163698.
6
Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience.南印度乳腺癌患者的激素受体状态(雌激素受体、孕激素受体)、人表皮生长因子-2及p53:一家三级护理中心的经验
Indian J Med Paediatr Oncol. 2015 Apr-Jun;36(2):117-22. doi: 10.4103/0971-5851.158844.
7
Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients.乳腺癌患者中与Ki-67表达相关的临床和组织病理学因素。
Oncol Lett. 2015 Mar;9(3):1046-1054. doi: 10.3892/ol.2015.2852. Epub 2015 Jan 7.
8
Intrinsically disordered proteins in cellular signalling and regulation.细胞信号转导和调控中的无规则卷曲蛋白
Nat Rev Mol Cell Biol. 2015 Jan;16(1):18-29. doi: 10.1038/nrm3920.
9
Immunohistochemical study of apoptotic marker p53 as a prognostic factor in breast cancer.凋亡标志物p53作为乳腺癌预后因素的免疫组织化学研究
Bull Exp Biol Med. 2014 Nov;158(1):84-7. doi: 10.1007/s10517-014-2698-3. Epub 2014 Nov 19.
10
[Expression of Ki67 and clinicopathological features in breast cancer].[Ki67在乳腺癌中的表达及临床病理特征]
Zhonghua Zhong Liu Za Zhi. 2014 Apr;36(4):273-5.